NCT07081646 2026-03-24
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT06097832 2025-07-10
NEXICART-2
Nexcella Inc.
Phase 1/2 Recruiting
NCT05839626 2025-06-12
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1/2 Terminated
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01707264 2018-08-28
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Prothena Biosciences Ltd.
Phase 1/2 Completed